Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Bayer AG
Deal Size : $253.0 million
Deal Type : Collaboration
Gubra ApS and Bayer AG Collaborate to Develop Next Generation Cardiorenal Treatments
Details : The collaboration will combine Gubra’s unique peptide drug discovery capabilities and use of advanced technologies with Bayer AG’s expertise in development of innovative medicines.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
September 20, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Bayer AG
Deal Size : $253.0 million
Deal Type : Collaboration